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Abstract 
Information on the higher-order structure is important in the development of 
biopharmaceutical drugs. Recently, hydrogen/deuterium exchange coupled with mass 
spectrometry (HDX-MS) has been widely used as a tool to evaluate protein conformation, and 
unique automated systems for HDX-MS are now commercially available. To investigate the 
potential of this technique for the prediction of the activity of biopharmaceuticals, granulocyte 
colony stimulating factor (G-CSF), which had been subjected to three different stress types, 
was analyzed using HDX-MS and through comparison with receptor-binding activity. It was 
found that HDX-MS in combination with ion mobility separation was able to identify 
conformational changes in G-CSF induced by stress, and a good correlation with the receptor-
binding activity was demonstrated, which cannot be completely determined by conventional 
peptide mapping alone. The direct evaluation of biological activity using bioassay is 
absolutely imperative in biopharmaceutical development, but HDX-MS can provide the 
alternative information in a short time on the extent and location of the structural damage 
caused by stresses. Furthermore, the present study suggests the possibility of this system 
being a versatile evaluation method for the preservation stability of biopharmaceuticals. 
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Introduction 
In the development of biopharmaceutical products, information on their higher-order structure 
is considered to be necessary in various situations such as comparability studies when 
changing manufacturing sites, investigations on unknown biological activity decline, and so 
on [1]. The US Food and Drug Administration (FDA) released a draft guidance for biosimilar 
drug development in 2012 [2], stating that structural information on a protein, not just the 
primary structure but also the higher-order structure, is important for its biological function. 
As such, an appropriate analytical method is required to evaluate the integrity of the protein 
structure. To characterize the higher-order structure of a protein with high resolution, X-ray 
crystallography and nuclear magnetic resonance (NMR) are now used as versatile tools. 
However, limitations remain in using these techniques for the high-throughput evaluation of 
biopharmaceuticals; X-ray crystallography requires crystallization of the protein, while 
application of NMR to large proteins (>30 kDa) is not practical. Furthermore, it is not easy to 
obtain structural information on heterogeneous mixtures of proteins with a small sample 
volume. 
Recently, hydrogen/deuterium exchange mass spectrometry (HDX-MS) has been recognized 
as a general tool for characterizing protein conformation. This technique cannot provide the 
three-dimensional structure of a protein with high resolution at the atomic level, but can detect 
changes in structure with peptide-length (3-25 amino acids) resolution [3]. The key 
advantages are that the technique requires only a small amount of the sample, a large 
molecular size is acceptable, and the analysis can be completed within a relatively short time. 
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With this technique, amide hydrogen atoms on the protein backbone are easily replaced with 
deuterium under deuterium-rich conditions, if they are located on the protein surface and are 
not involved in hydrogen bonding [4]. The rate of deuterium exchange depends on the 
microenvironment around the particular amide hydrogen, as well as the solution pH and 
temperature. The amide hydrogens that are in folded conformation cannot easily be 
substituted with deuterium, and the exchange rate is reduced in the solution at low pH or low 
temperature [5-7]. Since mass spectrometry can accurately determine the exact mass of a 
protein, it is easy to determine deuterium intake into the protein. At present, many 
applications of this technique, measuring the deuterium uptake at digested peptide levels to 
biopharmaceutical drug development have been reported, including conformational dynamics 
of antibodies (global HDX analysis, too) [8], epitope mapping of antibodies [9, 10], protein-
ligand interactions [11], and characterization of antibody aggregates [12]. 
In the present study, characterization of stress-exposed G-CSF, a major biopharmaceutical 
drug for neutropenia, was carried out. The three-dimensional structure of G-CSF has already 
been determined using X-ray crystallography [13, 14] and NMR [15], and the receptor 
recognition sites of G-CSF have also been elucidated [16-19] [PDB code 2D9Q]. So far, the 
effects of methionine oxidation on biological activity [20], and the conformational change by 
PEGylation to the N-terminal methionine [21], have been investigated for this protein. In this 
study, G-CSF was exposed to three types of stress: heating, photoirradiation, and oxidation. 
The resulting changes in structure and biological activity were analyzed using HDX-MS, ion 
mobility mass spectrometry (IM-MS), and enzyme-linked immunosorbent assay (ELISA). We 
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discuss here the relationship between the structural change and biological activity of G-CSF, 
and the potential of HDX-MS as a high-throughput evaluation tool for activity in 
biopharmaceutical drug development. 
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Experimental 
Sample Preparation 
G-CSF (Filgrastim BS 150 μg Syringe for Inj. MOCHIDA; Mochida Pharm. Co., Ltd, Tokyo, 
Japan) in the original formulation buffer [sodium acetate (undisclosed concentration), 5% D-
mannitol (w/v), 0.04 mg/mL polysorbate 80 at pH 4.0] was degraded in three ways: heat 
degradation (HD), photo degradation (PD) and forced oxidation (FO). In HD, the protein was 
incubated at 50°C for a month and underwent size-exclusion chromatography (SEC, see 
below for details) to isolate the main peak in order to remove aggregated species. In PD, 
based on the information given in the ICH guidelines [22], the protein was exposed to white 
fluorescent light over 1.2 million lux hours, as well as integrated near ultraviolet energy over 
200 watt hours/square meter. The FO sample was prepared by the addition of 30% hydrogen 
peroxide (Wako Pure Chemical Industries, Ltd., Osaka, Japan) to the protein solution to give 
a final concentration of 1%, and the resulting solution was incubated at 25°C for 24 h. As a 
final step, the solvent of the non-stressed (NS) and all the degraded proteins was exchanged to 
10 mM sodium acetate with 5% D-mannitol (w/v) at pH 4.0, and the protein concentration 
was adjusted to ca. 1 mg/mL (53 μM) using an ultrafiltration device (Amicon-Ultra; Millipore 
Corporation, Billerica, MA, USA). 
 
Size-Exclusion Chromatography (SEC) 
SEC was performed to evaluate the sample purity in terms of molecular size. A 10 μg aliquot 
of each sample was loaded onto a size-exclusion column (TSKgel G3000SWXL; Tosoh 
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Corporation, Tokyo, Japan) on an HPLC system (Agilent 1200 series; Agilent Technologies, 
Santa Clara, CA, USA). Separation was achieved with a solvent of 0.1 M sodium phosphate 
(Wako) and 0.15 M sodium chloride (Wako) at pH 2.5, at a flow rate of 1 mL/min, and 
monitored by a UV detector at 215 nm. To avoid non-specific adsorption, 2 mg/mL bovine 
serum albumin was injected before each sample injection [23, 24].  
 
Peptide Mapping 
Sites modified by the applied stress were determined by peptide mapping with HPLC-UV 
detection. A 50 μg aliquot of each sample was reconstituted in a denaturing solvent [5 M urea 
(MP Biomedicals, LLC., Santa Ana, CA, USA), 0.2 M tris (hydroxymethyl) aminomethane 
hydrochloride (Nacalai Tesque, Inc., Kyoto, Japan), 0.04 M methylamine hydrochloride 
(Sigma-Aldrich Corporation, St. Louis, MO, USA), 0.02 M dithiothreitol (Sigma-Aldrich)]. 
Digestion with Endoproteinase Glu-C (Roche Diagnostics, Indianapolis, IN, USA) was 
performed with an enzyme to substrate ratio of 1:25 at 25°C for 18 h. The digested samples 
were separated with a reversed-phase column (VYDAC C4 214TP52, 2.1 mm × 250 mm, 5 
μm particle diameter; Alltech Associates, Inc., Deerfield, IL, USA) by a gradient elution of 
solvent A [0.1% trifluoroacetic acid (HPLC grade; Wako)] and solvent B [90% acetonitrile 
(HPLC grade; Wako) / 10% water / 0.1% trifluoroacetic acid] on a UPLC system (Waters 
Corporation, Milfold, MA, USA). Peptides were eluted by the following gradient program: 
2% B (2 min), 2%−30% B (28 min), 30%−50% B (55 min) and 50%−98% B (5 min), at a 
flow rate of 0.2 mL/min and detected by UV at 214 nm [25]. Mass information was collected 
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using a quadrupole time-of-flight mass spectrometer (SYNAPT G2 HDMS; Waters) in the 
MSE mode.  
 
Enzyme-Linked Immunosorbent Assay (ELISA) 
ELISA was performed to assess the receptor binding activity of samples. An appropriate 
amount of each sample was mixed with a blocking solution [2 mg/mL I-Block (Applied 
Biosystems, Carlsbad, CA, USA) in PBS], resulting in G-CSF concentrations of 400, 80, 16, 
3.2, 0.64, 0.128, and 0.0256 ng/mL. These solutions were then introduced into each well in 
the 96-well microplate solid-phased with G-CSF receptor (Recombinant Human GCSFR/Fc 
Chimera; Sino Biological Inc., Beijing, China). After incubation at room temperature, anti-
human G-CSF antibody (Human G-CSF Biotinylated Antibody; R&D Systems Inc., 
Minneapolis, MN, USA) and avidin-labeled peroxidase (Pierce, Thermo Scientific, Rockford, 
IL, USA) were added, and reacted with the peroxidase substrate (TMB Microwell Peroxidase 
Substrate System; KPL Inc., Gaitherburg, MD, USA). Receptor binding activity could be 
determined by the absorbance at 450 nm using a microplate reader. The assays were carried 
out three times and the average was calculated. 
 
Ion Mobility Mass Spectrometry (IM-MS) 
IM-MS was performed to investigate the molecular size distribution in the gas phase. Samples 
reconstituted in 10 mM ammonium acetate at pH 4.0 were subjected to analysis with 
SYNAPT G2 HDMS using metal-coated borosilicate glass capillaries (nanoflow probe tips 
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thin walled; Waters). Each experimental parameter was set as follows: ESI capillary voltage 
0.8 kV, source temperature 50°C, sampling cone voltage 40 V, IMS wave velocity 740 m/s, 
and IMS wave height 40 V. The data were acquired at m/z 500−4000 every 1 s, and 
accumulated for 10 min.  
 
H/D Exchange Mass Spectrometry (HDX-MS) 
HDX-MS was performed to evaluate the higher-order protein structure in solution. An 
automated HDX System (Waters) coupled with SYNAPT G2 HDMS was used in all 
experiments. Each sample was diluted 20-fold by a blank solution [10 mM sodium acetate 
(Wako) at pH 4.0] or a deuterated solution [10 mM sodium acetate in D2O (Sigma-Aldrich) at 
pD 4.0 (pD = pHread + 0.40) [26, 27]]. The samples were then incubated for 0 s (blank, no 
deuteration), 10 s, 1, 12, 60, and 240 min (deuteration) at 25°C, and subsequently quenched 
by mixing with an equal volume of the quench solution [200 mM sodium acetate, 1.5 M 
guanidine hydrochloride (MP Biomedicals), 0.5 M tris(2-carboxyethyl)phosphine (Pierce)] 
[21] at 4°C. The quenched samples were then loaded onto an online pepsin-digestion column 
(immobilized pepsin column, 2.1 mm × 30 mm; Applied Biosystems), in which the  digestion 
and peptide trapping were performed for 4 min at 20°C at pH 2.5 (pH adjusted by formic 
acid), and the peptides were eluted at a flow rate of 250 μL/min. The digested peptides were 
then introduced to a UPLC column (ACQUITY UPLC BEH C18, 1.0 mm × 100 mm, 1.7 μm 
particle diameter; Waters) at 0°C. The peptides were separated with a gradient elution of 
solvent A (0.1% formic acid) and solvent B (0.1% formic acid in acetonitrile) [8%−40% B (6 
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min), 40%−90% B (0.5 min) and 90% B (1.5 min)] at a flow rate of 30 μL/min. The ion 
mobility function was also utilized to effectively separate the peptides. The IMS wave 
velocity and IMS wave height were set at 650 m/s and 40 V, respectively. The extent of back-
exchange was regarded as around 30% from the analysis of highly deuterated peptide standard. 
Because all the experiments were performed under identical condition, the correction of 
deuterium level was not implemented as described elsewhere [6, 28]. Based on the three 
independent repetitive experiments (different days) of the NS sample, the standard deviation 
(SD) of deuterium uptake levels at each labeling time point and their sum of at all labeling 
time points were ± 0.17 Da and ± 0.48 Da respectively, which are similar to the previously 
reported values [21, 28]. The values of 3 SD (i.e., ± 0.5 Da), for each labeling time point and 
± 1.4 Da for the sum of the levels at all labeling time points, were considered as appropriate 
criteria to judge significant difference. 
The peptic peptides of undeuterated protein were identified by the analytical software, 
ProteinLynx Global SERVER (Waters). Then, all the data including deuterated samples were 
processed with another analytical software, DynamX (Waters). The experiments were 
performed in triplicate. 
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Results and Discussion 
Peptide Mapping of Stress-Exposed G-CSF Monomer 
To identify the exact characteristics of the G-CSF monomer, impurities in the samples, such 
as artificial aggregates, are undesirable. Under the HD condition, the amount of artificial 
aggregates increased depending on the storage time, so they were removed by SEC 
fractionation, and the major peak corresponding to the G-CSF monomer was isolated. 
Because no significant impurity was recognized in the SEC chromatograms of the other 
samples (NS, PD, and FO), the fractionation process was skipped for them. Figure 1 shows 
the SEC chromatograms of the NS, fractionated HD, PD, and FO samples. Only a single peak 
appeared at the same retention time, suggesting that all four samples have an identical purity 
profile and that impurities of a different size do not exist in the sample. 
Next, peptide mapping was performed to characterize the modification in each degraded G-
CSF (Figure 2). The NS, HD, and PD samples exhibited similar chromatograms, 
demonstrating that heat and photo stresses do not cause any modification to the protein. In 
contrast, three peaks (marked as a, b, and c) disappeared, while three novel peaks (a*, b*, and 
c*) appeared in the FO sample. Using LC/MSE analysis, these peaks were revealed to contain 
oxidized methionine residues: Met127 and Met138 in peak a* (Leu125−Glu163), Met1 in peak b* 
(Met1−Glu20), and Met122 in peak c* (Leu100−Glu124), as summarized in Table 1. No other 
modification was detected in the FO sample. This is consistent with previously reported data 
[20].  
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ELISA of Stress-Exposed G-CSF Monomer 
To assess the receptor binding activity, ELISA was performed for each sample in triplicate. In 
this experiment, the absorbance at 450 nm reflects the level of interaction between the sample 
proteins and the G-CSF receptor. The results are summarized in Table 2. Relative receptor 
binding activity was calculated against the original G-CSF drug product (reference material). 
Considering the SD value of this ELISA experiment (ca. 4.5%, data not shown), and the 
dispersion of the measured values, the receptor binding activity of the HD and PD samples are 
considered to be almost identical (83%–89%) to the NS sample, whereas the FO sample 
showed a significant decrease (46%). The results suggest that oxidation stress might have 
contributed to the decline in the receptor binding activity of the FO sample, whereas other 
stresses had little effect. 
 
IM-MS of Stress-Exposed G-CSF Monomer 
To characterize the higher-order structure of the stress-exposed samples, IM-MS was 
performed and the collision cross-section distribution in the gas phase was obtained. In the 
present study, we carried out ESI-IM-MS analysis of the samples in 10 mM ammonium 
acetate solution at pH 4.0, which is similar to the original solvent of the drug product [sodium 
acetate (undisclosed concentration, pH 4.0), 5% D-mannitol (w/v), 0.04 mg/mL polysorbate 
80]. In the mass spectra of the four G-CSF samples, multiply charged ions with 6+ through 
19+ were observed, as shown in Figure 3a. 
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The most intense peak (8+) was picked up, and its driftgram was plotted (Figure 3b). The drift 
time of the stress-exposed samples, especially FO, shifted slightly to a later time, which 
suggests that the stress-exposed G-CSF structure was relaxed to some extent. As the 
resolution of ion mobility separation is not very high, a substantial change in the structure is 
needed to clearly separate protein ions using ion mobility spectrometry, especially for large 
proteins. A slight change in the driftgram would thus imply that the conformational changes 
of the degraded samples are insignificant. 
 
HDX-MS of Stress-Exposed G-CSF Monomer 
For further investigation into the conformation of the stress-exposed G-CSF, HDX-MS was 
performed. First, experimental conditions were optimized in order to achieve a high score in 
the sequence coverage. By simple LC/MSE analysis of peptic peptides, the score of the 
sequence coverage achieved was less than 90% (data not shown), which is not high enough to 
extensively investigate the complete protein conformation. This might be due to the steep LC 
gradient, which allows for rapid elution of peptides to avoid back-exchange of the amide 
hydrogens. It proved difficult to resolve the peptides well using the short-time elution. To 
accomplish a high resolution of the peptides with an identical LC gradient, IMS separation 
was added to the measurement scheme of LC/MSE. When MSE measurement was performed 
in combination with IMS separation, co-eluting peptides in the LC chromatogram could be 
separated by an additional dimension, drift time, which resulted in accurate identification of 
peptic fragments and improved sequence coverage [29]. It was found that the observed 
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peptides covered all receptor recognition sites, including site II (major: residues Lys17-Lys24 
and Leu109-Asp113) and site III (minor: residues Tyr40-Ser54 and Phe145-Arg148) (Figure 4) [19] 
[PDB code 2D9Q]. The supplemental use of IMS improved the sequence coverage up to 97%, 
as shown in Figure 4. MSE experiments in combination with IMS were carried out two more 
times, and high scores of sequence coverage (91% and 93%) were reproducibly obtained.  
Next, HDX-MS was performed on the NS, HD, PD and FO samples. Supplementary Figure 
S-1 shows deuterium uptake curves for the peptides derived from these samples. The 
observed mass difference of each peptic peptide between the NS and stress-exposed G-CSF 
was analyzed in detail. Figure 5 shows a summary of the results for the first trial of HDX-MS. 
The x-axis shows the observed peptide, and the y-axis shows the mass difference calculated 
by subtraction of the observed mass of stress-exposed G-CSF from that of NS. The vertical 
black bar shows the sum of the mass difference at each time point. In the difference chart of 
the NS versus HD sample (Figure 5a), the color plots and vertical bars converged at the center 
line (at 0.0) and the mass differences for almost all of the peptides were insignificant 
(significance criteria are ± 0.5 Da for the color plots and ± 1.4 Da for the vertical bars, as 
mentioned in the Experimental section), which means that no significant change in their 
higher-order structure was recognized by HDX analysis. The difference chart of the NS 
versus. PD sample (Figure 5b) demonstrates that deuterium uptake in the NS and PD samples 
are similar, but all the plots and bars are on the PD side. This may suggest that 
photoirradiation induced a slight relaxation in the protein structure. However, considering the 
significance criteria, the difference in deuterium uptake between the NS and PD samples can 
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be regarded as insignificant and can be ignored. In contrast, in the case of the FO sample, 
significant differences were observed in a broad range of the sequence in the difference chart 
(Figure 5c). Supplementary Figure S-2 and S-3 show typical mass spectra for the peptides at 
each time point; peptide 93-104 did not show a significant difference in deuterium uptake 
between the NS and FO samples, wehreas peptide 162-175 presented a considerable 
difference between the two samples. In particular, the N- and C-terminal regions including 
receptor recognition sites show a large negative extension in the vertical bars, implying that 
the FO sample has a more extended structure than the NS sample, resulting in high deuterium 
intake. Since the peptides that cover the receptor recognition site II exhibit large negative 
values in their relative fractional uptake scores, it is likely that conformational changes 
occurred mainly around site II. In addition, the C-terminal region from Ala142 through Pro175 
showed a big increase in deuterium uptake, suggesting that a drastic structural change also 
occurred in this region. Considering that ELISA showed a significant drop in receptor binding 
activity for the FO sample, a considerable degree of structural change in these regions is 
likely to have caused the large reduction in activity.  
Peptide mapping of the FO sample determined that four methionine residues were specifically 
oxidized, and its ELISA revealed a significant drop in the receptor binding activity. Since the 
four identified oxidized methionine residues are not located on the receptor recognition sites 
[19], the structure-activity relationship cannot be fully revealed using only sequence analysis 
and ELISA. In contrast, HDX-MS of the FO sample showed a drastic increase in deuterium 
uptake in a rather broad region, including the receptor binding sites. All four methionine 
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residues were included in the peptides that showed an increase in deuterium uptake. In a 
previous paper, chemical modification and site-directed mutagenesis were carried out to 
determine the order of methionine oxidation (Met1 > Met138 > Met127 >> Met122) and to 
correlate the effects of oxidation on the stability and biological activity of G-CSF [20]. 
However, in the present study, it was possible and quite easy to investigate the relationship 
between the conformational changes and receptor-binding activity using HDX-MS. As 
demonstrated here, HDX-MS is a promising tool for obtaining structural information on 
biopharmaceuticals within a short time in order to verify their biological activity.  
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Conclusions 
In this study, three kinds of degraded samples were prepared and assessed using various 
analytical techniques. SEC and peptide mapping demonstrated that the samples have an 
identical purity profile and primary structure, except for methionine oxidation in the FO 
sample. ELISA data showed a decrease in receptor binding activity for the FO sample, but 
IM-MS could not significantly detect this aspect. On the contrary, HDX-MS could sensitively 
detect the change in the higher-order structure, and showed a good correlation with receptor 
binding activity for the stress-exposed samples. 
In the development of biopharmaceutical products, the importance of higher-order structure 
evaluation increases every year. In this study, we found that HDX-MS is a promising tool for 
detecting conformation changes in G-CSF, and can easily provide the information on the 
structural damage by stress. This technique is also quite advantageous in that only a small 
amount of sample and a short time are required for analysis. Further studies may be required, 
but HDX-MS shows great potential as an indispensable tool in the biopharmaceutical drug 
development.  
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Table 1.  Glu-C Peptides with Methionine Residues 
Peak Sequence Oxidized methionines 
a Leu125−Glu163  
a* Leu125−Glu163 Met127, Met138 
b Met1−Glu20  
b* Met1−Glu20 Met1 
c Leu100−Glu124  
c* Leu100−Glu124 Met122 
 
 
 
Table 2.  Receptor Binding Activity Obtained Using ELISA 
Samples 
Receptor binding activity (%)* 
# 1 # 2 # 3 Average 
(n=3) 
NS 105 103 98 102 
HD 97 89 81 89 
PD 91 75 84 83 
FO 67 37 35 46 
*: Relative activity against G-CSF drug product (reference material). 
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Figure 1.  SEC chromatograms of the NS (a), HD (b), PD (c) and FO (d) samples. 
Only the main peak was clearly observed, and impurities such as aggregates did not 
appear in any chromatograms. 
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Figure 2.  UV chromatograms of the peptides from the NS (a), HD (b), PD (c) and FO 
(d) samples, generated by Glu-C digestion. Only the FO sample showed the peak 
shifts corresponding to methionine oxidation. Details of the oxidized peptides are 
summarized in Table 1. 
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Figure 3.  ESI mass spectrum of the NS sample (a) and driftgrams of 8+ charged 
ions of the stress-exposed and non-stressed G-CSF (b). Driftgrams of the NS, HD, 
PD and FO samples were overlaid with the color code described in the figure. The 
FO sample showed a slight delay in the peak in terms of the drift time. 
 
 
Figure 4.  Peptic peptides of G-CSF identified by MSE experiments. Four receptor 
recognition sites (site II and site III) are indicated on the amino acid sequence of G-
CSF [19] [PDB code 2D9Q]. The figure was drawn using the free software “MS tools” 
described in [30]. 
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Figure 5.  Difference-analysis charts (upper panel) of the HD (A), PD (B), and FO (C) 
samples (lower panel) compared with the NS sample, as obtained from the first trial 
of HDX-MS. The x-axis shows the common peptides of the two samples (red braces 
indicate the peptides that include receptor recognition sites), and the y-axis shows 
the mass difference calculated by subtraction of the observed mass value of the HD, 
PD, and FO samples from that of the NS sample. The vertical black bar shows the 
sum of each time point’s mass difference. Based on the results, the FO sample 
shows a significant difference relative to NS; in particular, the N- and C-terminal 
regions including receptor recognition sites show a significant increase in deuterium 
uptake. This suggests that the higher-order structure of the FO sample is rather 
loosened, especially around both end regions. Similar results were obtained from the 
other two independent experiments. 
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Supplemental Information 
 
Figure S-1.  Deuterium uptake curves of the peptides 1/5 
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Figure S-1.  Deuterium uptake curves of the peptides 2/5 
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Figure S-1.  Deuterium uptake curves of the peptides 3/5 
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Figure S-1.  Deuterium uptake curves of the peptides 4/5 
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Figure S-1.  Deuterium uptake curves of the peptides 5/5 
Deuterium uptake transition from 10 s to 240 min are indicated for the first trial of 
HDX of the NS, HD, PD and FO samples. 
Peptide sequence, position and monoisotopic molecular mass are shown in the 
upper left corner in each panel. 
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Figure S-2.  Mass spectra of peptide 93-104 of the NS (left) and FO (right) samples 
No significant difference was found between each two mass spectra. 
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Figure S-3.  Mass spectra of peptide 162-175 of the NS (left) and FO (right) samples 
Peptide 162-175 of the FO sample demonstrated a larger mass increase than that of 
NS. 
